Year-over-year, this metric grew by 2.7%, from $962.64M to $989.03M. Over 2 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 11.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $295.50M | $48.60M | $0.00 | $580.64M | $355.23M | $64.94M | $0.00 | $800.32M | $195.14M | $28.93M | $994.02M | $68.32M | $104.26M | $962.64M | $140.99M | $19.57M | $0.00 | $989.03M |
| QoQ Change | — | -83.6% | -100.0% | — | -38.8% | -81.7% | -100.0% | — | -75.6% | -85.2% | >999% | -93.1% | +52.6% | +823.3% | -85.4% | -86.1% | -100.0% | — |
| YoY Change | — | — | — | — | +20.2% | +33.6% | — | +37.8% | -45.1% | -55.5% | +24.2% | -65.0% | +260.5% | -3.2% | +106.4% | -81.2% | — | +2.7% |